How Optina Diagnostics Uses Castor EDC In Research Of Earlier Disease Detection

Experts estimate that nearly half of individuals living with dementia remain undiagnosed. Detecting the disease earlier could significantly enhance the quality of life for both patients and caregivers, in addition to potentially saving the US healthcare system billions of dollars. With the paramount objective of early disease detection, Optina Diagnostics is spearheading the development of a groundbreaking solution.

At the core of their innovation lies a sophisticated combination of a hyperspectral camera and artificial intelligence (AI). This pioneering technology aims to identify early signs of Alzheimer’s disease directly through the eye. By leveraging the unique capabilities of hyperspectral imaging and AI-driven analysis, Optina Diagnostics seeks to revolutionize the diagnostic process for Alzheimer’s, offering hope for earlier intervention and improved outcomes for those affected by the disease.